Aktie A3D54P CORBUS PHARMACEUTICALS HOLDINGS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Corbus Pharmaceuticals Holdings, Inc.

Aktien

A3D54P

US21833P3010

CRBP

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:00:00 28.06.2024 		% 5 Tage % 1. Jan.
45,25 USD +3,12 % Intraday Chart für Corbus Pharmaceuticals Holdings, Inc. +6,52 % +649,17 %
12.06. Transcript : Corbus Pharmaceuticals Holdings, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 02:40 PM
11.06. CORBUS PHARMACEUTICALS HOLDINGS, INC. : Bewertung von RBC Capital Markets kaufen ZM

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to S&P Biotechnology Select Industry Index
Corbus Pharmaceuticals Reaches 2-Year High After Drug Results
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024
Corbus Pharmaceuticals Presents Positive Clinical Update on SYS6002 (CRB-701) at ASCO Conference
Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting
Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
Corbus Pharmaceuticals: Q1 Earnings Snapshot
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum
Certain Restricted Stock Units of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.
Certain Warrants of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.
Certain Options of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.
Certain Common Stock of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting
Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
Corbus Pharmaceuticals Holdings, Inc. Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
Corbus Pharmaceuticals Files Mixed Shelf
Health Care Climbs on Risk Appetite -- Health Care Roundup
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3D54P Aktie
  4. Nachrichten Corbus Pharmaceuticals Holdings, Inc.
  5. Andere Sprachen